Drooling Medication

Updated: Aug 03, 2018
  • Author: Neeraj N Mathur, MBBS, MS, DNB(ENT), MNAMS, FAMS; Chief Editor: Arlen D Meyers, MD, MBA  more...
  • Print

Medication Summary

Anticholinergic agents inhibit activation at muscarinic receptors, and at best, decrease the volume of drooling. At tolerable anticholinergic doses, drooling is unlikely to completely cease.

Botulinum toxin leads to partial or complete muscle paralysis by inhibiting acetylcholine release at the neuromuscular synaptic end plate. It also blocks the release of acetylcholine at the cholinergic synapses of the autonomic nervous system; thus, this toxin can block cholinergic parasympathetic secretomotor fibers of the salivary gland. IncobotulinumtoxinA has received FDA approval for the treatment of chronic sialorrhea.


Neuromuscular Blockers, Botulinum Toxins

Class Summary

Injection of incobotulinumtoxinA into the parotid and submandibular glands has been approved by the FDA for adults with chronic sialorrhea owing to various neurologic disorders, including Parkinson disease, amyotrophic lateral sclerosis, cerebral palsy, and stroke.

IncobotulinumtoxinA (Xeomin)

Blocks cholinergic transmission at the neuromuscular junction by inhibiting acetylcholine release from the peripheral cholinergic nerve endings. It is indicated for adults with chronic sialorrhea.